Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

Open access
Carvajal, Richard D., Butler, Marcus O., Shoushtari, Alexander N., Hassel, Jessica C., Ikeguchi, Alexandra, Hernandez-Aya, Leonel, Nathan, Paul, Hamid, Omid, Piulats, Josep M., Rioth, Matthew, Johnson, Douglas B., Luke, Jason J., Espinosa, Enrique, Leyvraz, Serge, Collins, Laura, Goodall, Howard M., Ranade, Koustubh, Holland, Chris, Abdullah, Shaad E., Sacco, Joseph J., Sato, Takami · 2022 · Nature Medicine

Abstract

In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2–10%), the 1 year overall survival rate was 62% (95% CI: 53–70%) with a median overall survival of 16.8 months (95% CI: 12.9–21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02015-7

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 160

Metadata

Authors
Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., Johnson, D. B., Luke, J. J., Espinosa, E., Leyvraz, S., Collins, L., Goodall, H. M., Ranade, K., Holland, C., Abdullah, S. E., Sacco, J. J., & Sato, T.
Venue
Nature Medicine
Published
2022-10-13
Volume
28
Issue
11
Pages
2364-2373
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4305015938
Cited by
160
References
4
FWCI
25.83
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. https://app.cochat.ai/papers/10.1038/s41591-022-02015-7
The paper
Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., Johnson, D. B., Luke, J. J., Espinosa, E., Leyvraz, S., Collins, L., Goodall, H. M., Ranade, K., Holland, C., Abdullah, S. E., . . . Sato, T. (2022). Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-022-02015-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.